UK markets closed

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.3300-0.6700 (-16.75%)
At close: 04:00PM EDT
3.4300 +0.10 (+3.00%)
After hours: 07:37PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 48.31M
Enterprise value 12.41M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.38
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.88
52-week change 357.82%
S&P500 52-week change 326.49%
52-week high 34.4900
52-week low 31.5600
50-day moving average 32.7928
200-day moving average 32.0828

Share statistics

Avg vol (3-month) 31.45M
Avg vol (10-day) 3130.09k
Shares outstanding 514.51M
Implied shares outstanding 614.51M
Float 84.93M
% held by insiders 11.29%
% held by institutions 175.06%
Shares short (30 Apr 2024) 44.1M
Short ratio (30 Apr 2024) 41.02
Short % of float (30 Apr 2024) 439.57%
Short % of shares outstanding (30 Apr 2024) 428.29%
Shares short (prior month 28 Mar 2024) 4195.73k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 304 Apr 2019
Ex-dividend date 4N/A
Last split factor 21:18
Last split date 304 Apr 2019

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-12.67%
Return on equity (ttm)-15.87%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -7.97M
Net income avi to common (ttm)-6M
Diluted EPS (ttm)-0.4200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)35.9M
Total cash per share (mrq)2.47
Total debt (mrq)48k
Total debt/equity (mrq)0.14%
Current ratio (mrq)23.19
Book value per share (mrq)2.42

Cash flow statement

Operating cash flow (ttm)-4.95M
Levered free cash flow (ttm)-3.84M